---

---

trial   source : Alteritytherapeutics.com   

save search

---

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
Published: 2023-11-07 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -13.19% | O: 5.96% H: 8.43% C: 6.43%
ath434 system trial therapeutics phase 2

---

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
Published: 2023-07-26 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -26.35% | O: 2.89% H: 5.8% C: 3.5%
trial therapeutics phase 2

---

Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
Published: 2023-05-09 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -29.66% | O: 0.34% H: 0.0% C: -1.71%
ath434 australia global system trial therapeutics phase 2

---

Alterity Therapeutics Enrols First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Published: 2023-04-04 (Crawled : 02:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -25.82% | O: -1.73% H: 3.61% C: 3.61%
ath434 system trial therapeutics phase 2

---

Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Published: 2023-03-15 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -21.84% | O: 7.28% H: 5.0% C: -0.54%
ath434 system trial therapeutics phase 2

---

Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Published: 2023-03-08 (Crawled : 04:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -37.23% | O: 2.49% H: 0.57% C: -0.92%
ath434 system trial therapeutics phase 2

---

Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
Published: 2023-02-16 (Crawled : 02:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -32.23% | O: 4.65% H: 3.81% C: 2.86%
ath434 trial therapeutics authorization phase 2

---

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Published: 2023-01-24 (Crawled : 23:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -47.42% | O: -2.06% H: 5.66% C: 2.63%
ath434 treatment system trial therapeutics phase 2

---

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Published: 2023-01-09 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -41.7% | O: 1.46% H: 2.22% C: -2.82%
ath434 treatment system trial therapeutics

---

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Published: 2022-10-13 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -54.75% | O: -4.1% H: 6.41% C: 6.34%
ath434 treatment system australia trial therapeutics phase 2

---

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Published: 2022-08-25 (Crawled : 01:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -66.23% | O: 1.9% H: 8.85% C: -3.17%
ath434 treatment europe system trial therapeutics phase 2

---

Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Published: 2022-07-06 (Crawled : 01:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -67.3% | O: -2.17% H: 11.64% C: 1.84%
ath434 system trial therapeutics phase 2

---

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Published: 2022-06-22 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -66.41% | O: 0.43% H: 9.84% C: 4.79%
ath434 trial therapeutics authorization phase 2

---

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Published: 2022-06-02 (Crawled : 01:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -70.43% | O: -2.9% H: 11.93% C: 7.84%
ath434 treatment system trial therapeutics phase 2

---

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
Published: 2022-04-27 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -72.98% | O: 0.7% H: 2.6% C: -2.0%
ath434 trial therapeutics authorization phase 2

---

First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial
Published: 2021-12-13 (Crawled : 13:27) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K |

Health Technology

| -77.06% | O: 0.24% H: 3.2% C: 0.42%
ath434 phase 2 trial authorization

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---